Hugel, a global total medical aesthetics company, announced its 1Q24 consolidated financial results on the 9th, reporting revenue of KRW 74.3 billion, operating profit of KRW 24 billion, and net income of KRW 22.7 billion.
Hugel, a global total medical aesthetics company, announced that the company has received marketing approval from the U.S. Food and Drug Administration(FDA) on the 29th(local time) for 50 units and 100 units of its botulinum toxin Letybo.
Hugel, a global total medical aesthetics company, announced its 4Q 23 consolidated financial results on the 14th, reporting revenue of KRW 88.9 billion, operating profit of KRW 36.8 billion, and net profit of KRW 17.1billion, achieving another quarterly record-high. Sales revenue, operating profit, and net profit grew by 4%, 22.4%, and 451.6%, respectively, YoY.